Participated · Seed · Apr 2026

Jimini Health builds clinician-supervised AI infrastructure for behavioral health provider organizations, with a flagship platform called Sage that integrates into regulated clinical environments. Sage is designed so licensed clinicians maintain oversight of every patient interaction while enabling providers to deploy AI at scale. The company emphasizes compliance with regulatory requirements and direct integration with clinical workflows. Jimini plans to expand AI development across additional clinical settings and scale partnerships with large behavioral health providers nationwide using proceeds from its recent financing. Financially, the company raised a $17M Seed round led by M13, bringing total funding to over $25M. Jimini Health is based in New York and is led by CEO Luis Voloch.

Participated · Series A · May 2025

Rhino Federated Computing provides a platform for federated AI collaboration that enables enterprises to run AI and data science initiatives without centralizing data. The platform emphasizes protecting data ownership, complying with regulation, and accelerating multi‑party innovation. Founded in 2020 by Dr. Ittai Dayan and Yuval Baror, the company is based in Boston and maintains an R&D center in Tel Aviv. Rhino is already powering use cases including federated GenAI for biopharmaceutical R&D, healthcare data harmonization and federated collaboration, and financial‑crime and fraud detection for financial institutions. The company raised $15M in a Series A and has now raised over $30M to date. Rhino plans to use the new capital to scale capabilities across more customers and regulated sectors and to bring an enterprise‑grade federated AI solution to market. Rhino Health builds healthcare AI infrastructure that connects medical data sources with researchers while preserving patient privacy and IP confidentiality. The company develops solutions using federated learning and edge computing to enable secure, decentralized data processing and AI model training. Rhino Health has enabled partners to create networks of health systems, life sciences companies, and public sector organizations for cross-continent data collaborations. Led by CEO Dr. Ittai Dayan, the company emphasizes privacy-preserving approaches to accelerate healthcare research. The company received an investment intended to fund continued design of its federated and edge computing solutions; the amount was not disclosed. Rhino Health operates a platform that connects hospitals and AI developers, providing access to a large, continually updated, distributed dataset from a diverse group of patients. The core product enables clinical AI model development across different institutions and patient demographics. Rhino is collaborating with NVIDIA to bring federated learning into clinical settings and is using NVIDIA Clara to support cross-geography and cross-device model training. The company is a member of the NVIDIA Inception program and maintains an R&D center in Tel Aviv, Israel. Rhino closed a $5M seed financing round led by LionBird Ventures, with participation from Arkin Holdings and several angel investors. The company is led by CEO Ittai Dayan, MD, and CTO Yuval Baror.

Participated · Series A · May 2025

PhaseV is a Boston, MA-based company that specializes in AI/ML-driven clinical development. It provides a vertical AI platform that supports end-to-end clinical development from trial design through execution. The platform comprises four core applications: Trial Optimizer for Bayesian, adaptive, and fixed-trial optimization and implementation; Causal ML for heterogeneous treatment effect estimation to uncover hidden signals and identify high-potential subpopulations and endpoints; and Causal Disease Modeling to inform R&D and life-cycle management. Its Clinical Operations application offers Causal ML-driven site selection, site performance analytics, real-time trial progress monitoring, and integration of virtual control arms. PhaseV has delivered results for more than 30 pharma/biotech sponsors and CROs across therapeutic areas including neurology, oncology, immunology, GI and rare diseases. The company raised $50M in a Series A and plans to use the funds to expand operations and its development efforts; total funding to date is $65M. PhaseV develops causal machine learning technology to optimize clinical trial design and analysis, using proprietary ML to detect hidden signals in clinical data and extract actionable insights. The company provides an ML-driven adaptive process that can accelerate drug development and increase certainty through retrospective analysis and real-time trial adaptation. PhaseV offers two service lines: assessment and implementation of adaptive trial designs, and retrospective analysis to evaluate endpoints and subpopulations and support drug repurposing. Its approach has been applied across therapeutic areas including oncology, endocrinology, autoimmune diseases, and rare diseases. The company is led by CEO Dr. Raviv Pryluk and operates from Tel Aviv, Israel and Boston, MA. It plans to use the newly raised funds to expand operations and further development efforts.

Participated · Series A · Apr 2025

Phantom Neuro develops a minimally invasive neural interface platform called Phantom X to enable intuitive control of prosthetic limbs and robotic exoskeletons. Phantom X, originally developed at the Johns Hopkins University School of Medicine, is designed to restore natural movement by making assistive devices function as seamless extensions of the body. The company reported that its ASCENT study demonstrated 94% accuracy decoding real-time gestures across 11 essential hand and wrist movements. Phantom Neuro has received FDA Breakthrough Device and TAP designations for Phantom X, which may expedite regulatory approvals. The company plans to use new funding to accelerate preclinical testing, complete first-in-human trials, pursue regulatory submissions, and expand R&D for broader control applications beyond prosthetic limbs. Phantom Neuro is headquartered in Austin, Texas and has raised $28 million in total funding to date. Phantom Neuro develops a low-power, high-accuracy system intended to provide lifelike control of robotic orthopedic technologies. The company is positioned in the neurotech sector and is based in Austin, TX. Its core product targets control interfaces for robotic orthopedics, emphasizing low power consumption and high accuracy. The article does not disclose operating metrics such as revenue or user counts. Phantom Neuro announced a $6 million expanded seed financing, which increases its total funding to $9.5 million. The funding supports the company’s continued development of its control system for robotic orthopedic applications. Phantom Neuro is a neurotechnology company based in Austin, Texas and Baltimore, Maryland that is creating a system to enable lifelike control of robotic orthopedic technologies such as prosthetic limbs and exoskeletons. Its solution combines low-risk implantable sensors, AI, and enabling software to provide control of existing and next-generation orthopedic devices. The company is led by founder and CEO Dr. Connor Glass. Phantom Neuro raised seed funding to expand its operations and business reach. The $3.26M round was led by LionBird Ventures with participation from Draper Associates, Breakout Ventures, Blackrock Neurotech, Capital Factory, and private investors. As part of the financing, LionBird partner Robert Lord will join the board and LionBird Managing Partner Ed Michael will join as a board observer.

Led · Seed · Sep 2024

PatientPartner operates a patient mentorship platform designed to improve patient engagement and adherence across a range of disease states and treatment types. The company partners with pharmaceutical manufacturers, medical device companies, clinical research organizations (CROs) and other healthcare organizations to deliver scalable, technology-driven, personalized patient experiences. Led by CEO George Kramb, PatientPartner connects patients with mentors to support treatment journeys and improve outcomes. Today the platform has over 40,000 users and more than 500 mentors. The company raised seed funding to further expand the platform. The business focuses on scaling its mentorship network and technology integrations with healthcare stakeholders.